Developing the new diagnostic solution

Investing in the future of surge scale technology

To learn more, please contact our office

Antibody Testing

Developing a new diagnostic solution will drive economic recovery

The COVID-19 pandemic has posed several challenges to the global healthcare systems. The diagnostics area is recognized as one of the primary elements of efforts to contain the spread and circumvent its adverse impact globally

The global COVID-19 diagnostics market size is valued at USD 19.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027. 

FluroTest’s rapid antigen testing platform will be essential to furthering prompt and accurate viral detection at surge-scale levels, while helping to restore and stimulate social and economic activity.

Resources

The Pandemic Defense and Economic Recovery System Pitch Deck

From sports stadiums, airlines, cruise ships, and concert venues to healthcare facilities, corporate campuses, and universities,  to safely open to full capacity and maintain business continuity every environment requires:

  • accurate
  • affordable
  • accessible
  • fast
  • scalable technology

Latest Investor Presentation - January 14, 2020

We are developing a revolutionary Pandemic Defense and Economic Recovery System that will usher in the ‘the new normal’. It’s first testing system will be Antigen based with a throughput capacity of 2,500 tests per hour. Preliminary LOD 90x lower than the nearest competitor.

Please join us as Bill Phelan, CEO of FluroTest gives an executive presentation on the FluroTest Platform

In the News

FluroTech Retains Market-Making Services

CALGARY, Alberta, Jan. 27, 2021 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), is pleased to announce that is has engaged Venture Liquidity Providers